BioSpace News Archive

AbCellera, Viking Global Investors, and ArrowMark Partners announced that they have entered into a collaboration to advance new antibody drug programs with an aim to launch multiple asset-based companies.

Bio-Rad Laboratories, Inc. today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 PM Eastern Time (11:05 AM Pacific Time).

Syra Health Corp. (NASDAQ: SYRA), (“Syra Health” or the “Company”) announced today that it will report financial results for its first quarter 2024 ended March 31, 2024, on Thursday, May 9, 2024, before the market opens.

Somite Therapeutics, a tech-bio company leveraging big data and AI to introduce novel cell replacement therapies, today announced that the Company will present a poster at the upcoming American Society of Cell and Gene Therapy (ASGCT) Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and...

United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) with the clearance of its uMR Jupiter 5T MRI system.

Vesigen Therapeutics, Inc. today announced that the Company will be presenting two posters sharing new preclinical data from its engineered ARMMs platform at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.

Boston-MA- Gel4Med, an innovative biomaterials company, is thrilled to announce a three-year $1.75M collaborative grant awarded by the Congressionally Directed Medical Research Programs (CDMRP)/Department of Defense (DoD) to evaluate new therapeutic approaches with the potential to revolutionize the treatment landscape in spinal cord injury (SCI).

MannKind Corporation (Nasdaq: MNKD) will release its 2024 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 8, 2024.

Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended March 31, 2024.